Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: A single-centre, retrospective analysis

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Shenoy, Padmanabha D ^a   Bavaliya, Manish ^b   Sashidharan, Sujith ^b   Nalianda, Kaveri ^a   Sreenath, Sreelakshmi ^a  

^a Centre For Arthritis and Rheumatism Excellence (CARE)   (India)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cyclophosphamide; Mycophenolate mofetil; Scleroderma interstitial lung disease

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FORCED VITAL CAPACITY; HUMAN; INDUCTION CHEMOTHERAPY; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SCLERODERMA; SPIROMETRY; SYSTEMIC SCLEROSIS; COMPLICATION; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84971529355     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1015-0     Document Type: Article

References (22)

1. Taylor J, Bolster M. Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol. 2003;9(4):239-45.
2. D'Angelo W, Fries J, Masi A, Shulman L. Pathologic observations in systemic sclerosis (scleroderma). Am J Med. 1969;46(3):428-40.
3. Todd N, Lavania S, Park M, Iacono A, Franks T, Galvin J, et al. Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. J Heart Lung Transplant. 2010;29(2):188-94.
4. Ferri C, Valentini G, Cozzi F, Sebastini M, Michelassi C, La Montagna G, et al. Systemic sclerosis. Medicine. 2002;81(2):139-53.
5. Simeon-Aznar C, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O' Callaghan A, Solans-Laqué R, Palliza E, et al. Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. TORMJ. 2008;2(1):39-45.
6. Tashkin D, Elashoff R, Clements P, Goldin J, Roth M, Furst D, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-66.
7. Nihtyanova S, Brough G, Black C, Denton C. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology. 2007;46(3):442-5.
8. Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637. doi: 10.1155/2012/143637.
9. Fischer A, Brown K, Du Bois R, Frankel S, Cosgrove G, Fernandez-Perez E, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640-6.
10. Gerbino A, Goss C, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455-60.
11. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas L. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29(10):1167-8.
12. Liossis S, Bounas A, Andonopoulos A. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology. 2006;45(8):1005-8.
13. Swigris J, Olson A, Fischer A, Lynch D, Cosgrove G, Frankel S, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30-6.
14. Zamora A, Wolters P, Collard H, Connolly M, Elicker B, Webb W, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150-5.
15. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287-92.
16. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W, et al. Assessment of severity and prognosis in SSc. Clin Exp Rheumatol. 2003;21:S42-6.
17. Collard H, Loyd J, King T, Lancaster L. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007;101(9):2011-6.
18. Antoniou K, Wells A. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008;20(6):686-91.
19. Tashkin D, Elashoff R, Clements P, Roth M, Furst D, Silver R, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-34.
20. Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:1-7.
21. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62(2):97-9.
22. Khanna D, Seibold J, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. CRR. 2010;6(2):138-44.